RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.» Read More
Biotech's have had a very bad week, but the IBB has recovered a bit today. What's behind all the volatility, with Fed Hassan, Warburg Pincus, and CNBC's Meg Tirrell.
LONDON, Sept 29- The first patient has been treated in Britain in a pioneering trial of a new treatment co-developed by Pfizer and derived from embryonic stem cells designed for patients with a condition that can cause blindness. Specialists at London's Moorfields Eye Hospital said the operation, described as "successful", was the first of 10 planned for...
With the biotechnology sector tumbling, is this temporary? Or the beginning of a downward slide? Analysts weigh in.
David Seaburg, Cowen & Company, Jerry Castellini, CastleArk Management, discuss the biotech sector as the IBB heads into bear market territory.
The IBB, biotech ETF has officially entered bear market territory, and has fallen below the level where it was after the flash crash. CNBC's Brian Sullivan and Melissa Lee discuss.
CNBC's Meg Tirrell looks at events in biotech that could help the sector out of it's recent struggles. The Fast Money traders discuss the trade.
NBC News' Andrea Mitchell reports Turing Pharmaceuticals CEO Martin Shkreli will lower the price of Daraprim, which was raised 5,000 percent over the weekend. He says it will happen in the next few weeks.
Sept 22- A company formed by genome pioneer Craig Venter will offer clients of a South Africa- based insurance company whole exome sequencing- sequencing all protein-making genes in the human genome- at a price that marks yet another dramatic decline in the cost of gene sequencing, the two companies said on Tuesday. Venter's company, Human Longevity Inc, will...
A huge overnight price increase for an important tuberculosis drug has been rescinded after a public outcry, the NYT reports.
Kevin Gorman, Ph. D., President, CEO, Neurocrine Biosciences, explains how his company is up 144 percent so far this year.
Peder Holk Nielsen, CEO of Novozymes, says it has become tougher for renewables and biofuels to compete with fossil fuels.
Short sellers are continuing to target biotechnology stocks as one of the frothiest sectors in US equities staggers after a bruising August.
CNBC's Meg Tirrell reports on what could be a new era for U.S. medicine.
Fred Hassan, managing director of healthcare and consumer for Warburg Pincus, says we will see more M&A in the health care sector.
Aug 31- Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. Shares of BioTime Inc, a company that owns nearly 70 percent of Asterias, were little changed at $3.07. Asterias bought OPC-1 in 2013 from the erstwhile stem cell research leader...
Aug 31- Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. Asterias bought OPC-1 in 2013 from the erstwhile stem cell research leader Geron Corp, which decided to focus on developing cancer drugs. Asterias is looking to show recovery of...
Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.
Aug 21- The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug. The study, among patients with newly diagnosed brain cancer, is being conducted in Germany, the United Kingdom, the United States...
David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.
One biotech stock could see massive moves later this month, thanks to the meddling of hedge fund heavy hitter, Kyle Bass. CNBC's Meg Tirrell reports the latest.